Parabilis Medicines Plans ESMO 2026 Oral Presentation on Zolucatetide

What Happened Parabilis Medicines, Inc. (PBLS) filed an 8‑K (Item 7.01, Regulation FD Disclosure) on September 15, 2026, saying it intends to present updated clinical data from its ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The oral presentation is scheduled for Saturday, October 24 during a sarcoma-focused Proffered Paper session beginning at 2:45 pm CEST (8:45 am ET).

Key Details

• Filing date: September 15, 2026 (Form 8‑K, Item 7.01, Regulation FD Disclosure).
• Event: Oral presentation of updated Phase 1/2 zolucatetide data at ESMO Congress 2026, Madrid.
• Presentation time: Saturday, October 24 — Proffered Paper session starting 2:45 pm CEST (8:45 am ET).
• Patient population: desmoid tumor patients (ongoing Phase 1/2 study).

Why It Matters This disclosure informs investors that Parabilis plans to share new clinical data on zolucatetide at a major oncology conference, which could provide updated safety or efficacy information about its lead program in desmoid tumors. Conference presentations often influence clinical and investor perception of a drug’s progress; attendees and analysts may react to the data when it is presented. The 8‑K is a regulatory update (Regulation FD) to ensure fair public disclosure of the company’s intent to present these results.